Donald I. Abrams, MD
Professor, Clinical Medicine, UCSF
Program Member, UCSF Comprehensive Cancer Center
Box 0874, UCSF
San Francisco, CA 94143-0874
(415) 476-4082 x444
Brown University, Providence, RI, AB, 1972, Molecular Biology
Stanford Univ. School of Medicine, Stanford, CA, MD, 1977, Medicine
Kaiser Foundation Hospital, San Francisco, CA, 1980, Internal Medicine
Cancer Research Institute, UCSF, 1983, Hematology/Oncology
University of Arizona, 2004, Associate Fellowship in Integrative Medicine
July 1982 - June 1983
Assistant Research Physician, Cancer Research Institute, University of California San Francisco
July 1983 - June 1984
Clinical Instructor, Department of Medicine, San Francisco General Hospital and Cancer Research Institute, University of California San Francisco
July 1983 - present
Assistant Director, AIDS Activities, San Francisco General Hospital
July 1984 - July 1988
Assistant Clinical Professor, Department of Medicine, Cancer Research Institute, University of California San Francisco
July 1988 - 1992
Associate Professor of Clinical Medicine, University of California San Francisco
July 1985 - present
Chairman, Community Consortium of Bay Area HIV Health Care Providers
July 1992 - present
Professor of Clinical Medicine
Chief, Hematology-Oncology, San Francisco General Hospital
Abrams D, Chinn E, Volberding P, Lewis B, Conant M and Townsend R. Hematologic manifestations of Kaposi's sarcoma in homosexual men. AM J Clin Pathol 1984; 81:13-18.
Abrams Dl, Lewis BJ, Beckstead JH, Casavant C, Drew WL. Persistent diffuse Iymphadenopathy in homosexual men: Endpoint or Prodrome? Ann Intern Med 1984;100:801-808.
Abrams Dl, Kiprov DD, Goedert JJ, Sarngadharan MG, Gallo RC, Volberding PA. Antibodies to human T-lymphotropic virus type-lll antibodies and development of acquired immunodeficiency syndrome in homosexual men presenting with immune thrombocytopenia. Ann Intern Med 1985; 104:47-50
Bloom EJ, Abrams Dl, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA 1986; 256:491-493.
Abrams Dl, Kuno S, Wong R, Jeffords K, Nash M, Molaghan JB, Gorter R, Ueno R. Oral Dextran sulfate(UA001 ) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AlDS-related complex. Ann Intern Med 1989; 110:683688.
Leong G, Feigal D, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson M, Volberding P, Abrams Dl, and the San Francisco County Community Consortium. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco Community Prophylaxis Trial. NEJM 1990; 323:769-775.
Slome LR, Moulton JM, Huffine C, Gorter R, Abrams Dl. Physicians' attitudes towards assisted suicide in AIDS. JAIDS; 1992; 5:712-718.
Abrams DI, Mitchell TF, Child CC Shiboski SC, Brosgart CL, Mass M, and the Community Consortium. Clofazimine as prophylaxis for Disseminated Mycobacterium Avium Complex. J Inf Dis 167:1459-63, 1993.
Abrams DI, Goldman A, Launer C, Korvick J, Neaton JD, Crane L, et al and the Terry Beirn Comrnunity Programs for Clinical Research on AIDS, (CPCRA), NIAID, NIH, Washington, DC. Results of a randomized open- label comparison trial of ddI and ddC in HIV-infected patients who are intolerant of or have failed ZDV therapy: CPCRA 002. NEJM, 330:657-62,1994.
Northfelt DW, Charlebois, ED, Mirda MI, Child C, Kaplan LD, Abrams DI, and the Community Consortium. Continuous low-dose interferon-alpha therapy for HIV-related irnmune thrombocytopenic purpura. JAIDS, 8:45-50,1995.
Goldman AI, Carlin BP, Crane LR, Launer C, Korvick JA, Deyton L, Abrams DI. Response of CD4+ and clinical consequences to treatment using ddI or ddC in patients with advanced HIV infection. JAIDS 11:161-169, 1996.
Brosgart CL, Mitchell T, Charlebois E, Coleman R, Mehalko S, and Abrams DI. Off-label drug use in HIV diseases, JAIDS 12:56-62, 1996.
Burack JH, Cohen MR, Hahn JA.and Abrams DI. A pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms, JAIDS 12:386-93, 1996.
Saravolatz LD, Winslow D, Collins G, Hodges JS, Pettinelli C, Stein D, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams DI. A comparison of ZDV alone or in combination with didanosine or zalcitabine in HIV-infected patients with AIDS or fewer than 200 CD4-positive cells per cubic millimter. NEJM 335:1099-1106, 1996.
Slome LR, Mitchell TF, Charlebois E, Moulton Benevedes J, Abrams DI. Physician-assisted suicide and patients with human immunodeficiency virus disease. NEJM 336:417-421, 1997.
Deeks SG, Abrams DI. Genotypic resistance assays and antiretroviral therapy. Lancet, 349:1498-90, 1997.
Grant RM, Abrams DI. Not all is dead in HIV-1 graveyard. Lancet, 351:308-09, 1998.
Abrams, DI. Medical marijuana: Tribulations and trials. Journal of Psychoactive Drugs, 30:163-69, 1998.
Leiser RJ, Mitchell TF, Hahn JA, Slome LR, Abrams DI. Nurses attitudes and beliefs towards assisted suicide in AIDS. JANAC, 9:26-33, 1998.
Brosgart C, Louis TA, Hillman D, Craig C, Alston B, Fisher E, Abrams DI, Luskin-Hawk R, Sampson J. A randomized, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus Disease in HIV- Infected Individuals. AIDS, 12:269-277, 1998.
Wheeler DA, Gibert CL, Launer CA, Muurahainen N, Elion RA, Abrams DI, Bartsch GE and The Terry Beirn Community Programs for Clinical Research on AIDS. Weight loss as a predictor of survival and disease progression HIV infection. JAIDS, 18:80-85, 1998.
Brosgart C, Louis TA, Hillman D, Craig C, Alston B, Fisher E, Abrams DI, Luskin-Hawk R, Sampson J. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV- infected individuals. AIDS, 12:269-277, 1998.
Leiser RJ, Mitchell TF, Hahn JA, Slome LR, Abrams DI. Nurses1 attitudes and beliefs towards assisted suicide in AIDS. JANAC, 9:26-33, 1998.
Wheeler DA, Gibert CL, Launer CA, Muurahainen N, Elion RA, Abrams DI, Bartsch GE and the Terry Beirn Community Programs or Clinical Research on AIDS. Weight loss as a predictor of survival and disease Progression HIV infection. JAIDS, 18:80-85, 1998.
Cox L, Rouff JR, Markowitz M, Svedsen R, Abrams DI. Community Advisory Boards: Role in AIDS Clinical Trials. Health and Social Work, 23: 290-97, 1998.
El-Sadr W, Luskin-Hawk R, McCabe Yurik T, Abrams DI, John SL, Sherer R, Crane L, Labriola A, Caras S, Pulling C, and Hafner R. A randomized trial of daily and thrice weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in HIV-infected individuals. CID 29:775-83, 1999.
Cohen MR, Mitchell TF, Bacchetti P, Child C, Crawford S, Gaeddert A and Abrams DI. Use of a Chinese herbal medicine for treatment of HIV-associated pathogen-negative diarrhea. Integrative Medicine, 2:79-84, 1999.
Brosgart CL, Mitchell TF, Coleman RL, Dyner T, Stephenson KE, Abrams DI. Clinical experience and choice of drug therapy for human immunodeficiency virus. Clin Infect Dis 28:14-22, 1999
Corless IB, Abrams DI, Nicholas PK, McGibbon CA. The use of complementary and alternative therapies. AACN Clinical Issues 11:4-6,2000.
Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters M, Mannheimer S, Thompson M, Abrams DI, Brizz BJ, Ioannidis JPA, Merigan TC and the CPCRA 046 Study Team. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS, 14: F83-F93, 2000.
Eberly LE, Ohman PA, Neaton JD, Price RW, Abrams DI. Kaposi1s sarcoma and CNS disease: a real association or an artifact of the control group? AIDS, 14:995-1000, 2000.
Abrams DI, Steinhart C, Frascino R. Epoetin alfa improves quality of life in HIV-infected patients. International Journal of STD & AIDS, 11:1-7, 2000.
Abrams, DI. Potential interventions for HIV/AIDS wasting: an overview. JAIDS, 25:S74-S80, 2000.
Mulligan K, Tai VW, Algren H, Abrams DI, Leiser RJ, Lo JC, Schambelan M. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquire Immune Defic Syndr, 26:443-448, 2001.
MacArthur RD, Chen L, Mayers D, Besch CL, Novak R, van den Berg-Wolf M, Yurik T, Peng G, Schmetter B, Brizz B, Abrams D. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) Trial. Control Clin Trials, 22:176-90, 2001.
Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS, 16:543-550, 2002.
Abrams DI, JD Bebchuk, ET Denning, RT Davey, L Fox, HC Lane, J Neaton, J Sampson, R Verheggen, D Zeh, and N Markowitz for the Terry Beirn Community Programs for Clinical Research on AIDS. A randomized open-label study of the impact of two different doses of subcutaneous recombinant IL-2 on viral burden in patients with HIV-1 infection and CD4+ counts > 300/mm3: CPCRA 059. JAIDS, 29:221-231, 2002.
Emery S, Abrams DI, Cooper DA, Darbyshire JH, Duncan WR, Lane HC, Lundgren JD, Neaton JD and the ESPRIT study group The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International Trial: rationale, design, and methods of ESPRIT. Control Clin Trials, 23:198-220, 2002.
Eisenberg JNS, Wade TJ, Hubbard A, Abrams DI, Leiser RJ, Charles S, Vu M, Saha S, Wright CC, Levy DA, Jensen P, Colford JM. Associations between water treatment methods and diarrhea in HIV positive individuals. Epidemiology and Infection, 129:315-323, 2002.
Bredt BM, Higuera-Alhino D, Shade SB, Herbert S, McCune JM, Abrams DI. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. In press, Journal of Clinical Pharmacology, 42:82S-89S, 2002.
Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Van Rompaey SE, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN. CD4+ T-cell count outcomes in HIV-infected adults experiencing four years of sustained viral suppression on highly active antiretroviral therapy. AIDS, 17:1-9, 2003.
Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, McCune JM, Schambelan M. Short-term safety of cannabinoids in HIV infection: Results of a randomized, controlled clinical trial. Annals Intern Med, 139:258-266, 2003.
Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD. A Multicenter Randomized Trial of Structured Treatment Interruption in Patients with Multi-Drug Resistant Human Immunodeficiency Virus-1. New Engl J Med, 349:837-846, 2003.
Markowitz N, Bebchuk JD, Abrams DI. Nadir CD4+ T-cell count predicts response to subcutaneous recombinant interleukin-2. Clin Inf Disease, 37(8):e115-120, Epub 2003.